CTX0294885

Inhibitory assays

A panel of 10 kinases consisting of FAK, Flt3, JAK2, JAK3, CSF-1R, SRC, VEGFR3, Aurora A, LIMK1, and ROCK2 was initially used to evaluate kinase inhibition profiles. 15 μL assay reactions were performed in Greiner brand white 384-well, low-volume plates. All reactions contained assay buffer (10 mM HEPES pH 7.4, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 μM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM dithiothreitol), a N-terminally biotinylated peptide substrate (concentration 111 nM), and ATP at a concentration equaling the KM (ATP) of the kinase. The compounds were added in a volume of 100 nL from an 11-point-dilution series prepared in DMSO, positive and negative control reactions receiving the same volume of DMSO without compound. The kinases were added at predetermined concentrations, generally ranging between 0.2 and 8 nM, with the enzyme being omitted from negative control reactions. The reactions were incubated for 90 min at 30 °C and stopped by adding 5 μL of Stop buffer (10 mM HEPES pH 7.4, 25 mM NaCl, 100 mM EDTA, 0.01% (v/v) Tween-20) containing streptavidin-coated donor and antiphosphotyrosine (P-Tyr-100) acceptor beads. Plates were incubated for 4–6 h before being read on a PerkinElmer EnVision plate reader in HTS Alphascreen mode.

Cell lines

MDA-MB-231 Cells

Preparation method

The solubility of this compound in DMSO is > 21.9 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

1 μM

Applications

CTX-0294885 exhibited inhibitory activity against a broad range of kinases in vitro, and further developed it into a Sepharose-supported kinase capture reagent. Large-scale CTx-0294885-based affinity purification followed by LC-MS/MS led to the identification of 235 protein kinases from MDA-MB-231 cells, including all members of the AKT family that had not been previously detected by other broad-spectrum kinase inhibitors.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Zhang L, Holmes I P, Hochgrafe F, et al. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling[J]. Journal of proteome research, 2013, 12(7): 3104-3116.